Analyst Research Report Snapshot

Title:

OXFORD BIOMEDICA - PFIZER OPT-IN MILESTONE EXTENDS FUNDING RUNWAY

Price:

$10.00

Provider:

Edison Investment Research

Date:

29 Aug 2013

Pages:

6

Type:

AcrobatPDF

Companies referenced:

OXB.L

Available for Immediate Download
Summary:

Oxford BioMedica’s interim results confirm it is funded through to Q214, which is important since Sanofi is expected to make the key RetinoStat opt-in decision (assuming the clinical programme resumes in Q4) around that time. The production agreement with Novartis, coupled with a milestone from Pfizer, provides welcome cash flows and helps validate Oxford BioMedica’s expertise. Our valuation is unchanged at £60.1m.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.